Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Signalrx Pharmaceuticals Inc. has 1 pending office action in the Biotechnology & Pharmaceuticals technology area. Prosecution is currently limited to 1 distinct examiner and 1 distinct art unit.
NOLAN, JASON MICHAEL is the busiest examiner, holding 1 busiest examiner pending action. This examiner is responsible for the company's only 1 pending office action, centralizing the current prosecution activity.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| NOLAN, JASON MICHAEL | 1 | 66.6% | -27.2% |
| Art Unit | Apps |
|---|---|
| 1623 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17922045 | Methods of Use for Single Molecule Compounds Providing Multi-Target Inhibition to Treat Covid 19 | NOLAN, JASON MICHAEL | 1623 | §112Other | Non-Final OA | — | Pending | Oct 28, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSignalrx Pharmaceuticals Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jason Michael Nolan has the most, with 1 of Signalrx Pharmaceuticals Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
